

## Review Article

# ROS, Notch, and Wnt Signaling Pathways: Crosstalk between Three Major Regulators of Cardiovascular Biology

C. Caliceti,<sup>1</sup> P. Nigro,<sup>2</sup> P. Rizzo,<sup>1</sup> and R. Ferrari<sup>1</sup>

<sup>1</sup> Department of Cardiology and Laboratory for Technologies of Advanced Therapies (LTTA Center), University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy

<sup>2</sup> Centro Cardiologico Monzino (IRCCS), Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Milan, Italy

Correspondence should be addressed to C. Caliceti; [cristiana.caliceti@gmail.com](mailto:cristiana.caliceti@gmail.com)

Received 17 November 2013; Accepted 28 December 2013; Published 4 February 2014

Academic Editor: Tullia Maraldi

Copyright © 2014 C. Caliceti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reactive oxygen species (ROS), traditionally viewed as toxic by-products that cause damage to biomolecules, now are clearly recognized as key modulators in a variety of biological processes and pathological states. The development and regulation of the cardiovascular system require orchestrated activities; Notch and Wnt/ $\beta$ -catenin signaling pathways are implicated in many aspects of them, including cardiomyocytes and smooth muscle cells survival, angiogenesis, progenitor cells recruitment and differentiation, arteriovenous specification, vascular cell migration, and cardiac remodelling. Several novel findings regarding the role of ROS in Notch and Wnt/ $\beta$ -catenin modulation prompted us to review their emerging function in the cardiovascular system during embryogenesis and postnatally.

## 1. Introduction

Cardiovascular disease is the number one cause of death worldwide [1]. It has become clear that increases in reactive oxygen species ( $O_2^{\cdot-}$ ,  $H_2O_2$ , and  $\cdot OH$ ) represent a common pathogenic mechanism for cardiovascular diseases including atherosclerosis, hypertension, and congestive heart failure [2].

In the last decade the scientific community clarified the importance of low levels of ROS as key signaling molecules in physiological functions such as the regulation of cell signaling, proliferation, and differentiation [3]. Different authors provided scientific evidences regarding a sequential and direct link between Notch and Wnt signaling pathways in tuning endothelial cells (ECs) and cardiomyocytes functions and vascular morphogenesis [4].

The purpose of this review is to describe how ROS regulate Notch and Wnt pathways. Understanding the molecular mechanism regulated by ROS could lead to the development of new therapeutic approaches for cardiovascular diseases.

## 2. Role of ROS in Cardiovascular System

Vascular ROS formation can be stimulated by mechanical stress, environmental factors, platelet-derived growth factor

(PDGF), angiotensin II (AngII), and low-density lipoproteins [4–7]. Because many risk factors for coronary artery disease such as hyperlipidemia, hypertension, diabetes, and smoking increase production of ROS, it has been suggested that changes in vessel redox state are a common pathway in the pathogenesis of atherosclerosis [8–10].

A particularly important mechanism for ROS-mediated cardiovascular disease appears to be via stimulation of pro-inflammatory events [11]. These, in turn, cause endothelial cell (ECs) dysfunction that predisposes to atherosclerosis by augmenting thrombosis, inflammation, VSMC growth, and lipid accumulation. The strongest data that link AngII, oxidative stress, and ECs dysfunction are animal studies in which rats were made hypertensive to ~200 mm Hg by infusion of either AngII or norepinephrine. ECs dysfunction was observed only with AngII and correlated with increased superoxide production by arteries [12]. Similar results were obtained from the TREND and HOPE clinical studies which demonstrated that inhibiting AngII restores ECs function and decreases cardiovascular events [13, 14]. More recently, Harrison's lab has shown that AngII stimulates T cell inflammatory responses in a redox-dependent (NAD(P)H oxidases) manner that contributes to hypertension [15].

It has been previously reported that, in response to ROS, VSMC may secrete proteins that participate in autocrine/paracrine growth [16].

ROS are produced at low levels prevalently as byproducts of the mitochondrial electron transport chain and through NAD(P)H oxidase family. They play a physiologically important role in the regulation of various biological responses such as cell migration, proliferation, gene expression, and angiogenesis [17, 18].

NAD(P)H oxidase (Nox) enzymes are membrane-associated enzymatic complexes and structural homologues of phagocytic Nox (gp91phox/Nox2) and consist of both single (Nox1–Nox5) and dual (Duox1 and Duox2) oxidases [19]. ROS are generated by an electron transport through the membrane forming  $O_2^{\cdot-}$  that can further disproportionate forming hydrogen peroxide ( $H_2O_2$ ) or, in presence of nitric oxide ( $\cdot NO$ ), creating peroxynitrite (ONOO $^-$ ).

Nox2 and Nox4 are critical ROS-generating complexes in ECs; they are activated by various stimulants and agonists, for instance, VEGF. Nox1 isoform is more abundant in epithelium, even if it was detected also in ECs and VSMCs [20].

VEGF stimulates ROS production from Nox2 that in turn promotes VEGFR2 autophosphorylation through oxidation/inhibition of phosphatase enzymes. The result is an enhancement in cell proliferation, migration, and angiogenesis [21, 22].

Khatri et al. [23] have shown that vascular Nox2-derived ROS promotes VEGF expression and neovascularization in transgenic mice overexpressing p22phox, a binding partner of Nox. Nox4 is more abundantly expressed compared to Nox2 in ECs. Recently, Datla et al. [24] reported that Nox4 small-interference RNA (siRNA) inhibits VEGF-induced ECs migration and proliferation. Interestingly, Vallet et al. [25] showed that Nox4 expression is upregulated during ischemia-induced angiogenesis of mice. Gene knockout and overexpression studies on Nox4 suggest that Nox4-derived ROS have vascular protective function [26].

Urao and Ushio-Fukai [27] demonstrated that hindlimb ischemia increases Nox2-dependent ROS production in isolated bone marrow-derived mononuclear cells (BM-MNCs) and that postischemic neovascularization and mobilization of BM cells (BMCs) are impaired in Nox2 knockout mice concluding that Nox2-derived ROS regulate progenitor cell expansion and reparative mobilization in response to ischemia.

Furthermore, Nox1-dependent redox signaling pathway modulates the phosphatase PTP-PEST/PTPN12, an important regulator of endothelial cell migration and adhesion [28]. In particular, Nox1-derived ROS were found to promote intestinal mucosa wound repair by inactivating PTEN and PTP-PEST, with consequent activation of focal adhesion kinase (FAK) and paxillin [29].

### 3. Notch Signaling in the Cardiovascular System

Notch pathway is a highly conserved signaling system that controls cell fate decisions [30]. It is a short range communication system between two adjacent cells based on a ligand-activated receptor. In mammals there are four highly

homologous receptors (Notch 1, 2, 3, and 4) and five ligands (Delta-like ligands 1, 3, and 4 and Jagged 1 and 2). Both receptors and ligands are membrane-spanning proteins. Ligand binding induces a conformational change that allows the first proteolytic cut by “A Disintegrin And Metalloprotease,” ADAM (the principal involved are 10 and 17) [31] which removes the extracellular portion of Notch and creates a membrane-tethered intermediate that is a substrate for  $\gamma$ -secretase, a cleaving protease complex.  $\gamma$ -secretase in turn generates the active form of Notch (Notch intracellular fragment, NIC) which translocates to the nucleus where it binds the transcriptional factor CSL (CBF1, Suppressor of Hairless, Lag-1) also known as recombinant signal binding protein 1 for  $J\kappa$  (RBP- $J\kappa$ ). Such NIC binding displaces repressor molecules and promotes the recruitment of coactivator molecules. This in turn activates the transcription of specific Notch target genes such as Hes (hairy/enhancer of split), Hey (Hes-related proteins), Nrarp (Notch-regulated andrin repeat protein), cMyc, cyclin D1, and many other genes that control ECs proliferation, differentiation, and apoptosis as well as stem cells maintenance and angiogenesis [32].

Notch receptors 1, 2 as well as Jagged1, Delta-like ligand 1 and 4 (Dll1 and Dll4), are preferentially expressed in ECs and have a key role in developmental and postnatal angiogenesis. During early embryogenesis, Notch induces differentiation of angioblasts to ECs, whereas at later stages it controls specification of ECs into arterial and venous identity [33]. Mice embryos with single Notch1 or double mutations of Notch1 and Notch4 display severe defects in vascular development. In ECs, VEGF-A induces the formation of filopodia, conferring the so-called tip cells phenotype. Tip cells promote a line of angiogenesis while inhibiting branching by adjacent cells (called static or stalk cells) which need to remain angiogenically quiescent. VEGF-A promotes the expression of Dll4 and Notch activation in human ECs, resulting in downregulation of VEGFR2 in tip cells. Thus, this interplay between Notch and VEGF-A regulates angiogenesis with selective sprouting through the activation of the tip cells and suppression of branching through activation of stalk cells. Given its specificity in the regulation of angiogenesis, the endothelial Dll4-mediated Notch signaling has been used as target for intervention in induction of new arteries or inhibition of tumor angiogenesis [34]. VEGFR3, the main receptor for VEGF-C, is also strongly modulated by Notch. Notch inhibition in mouse retina caused an increase in protein levels of VEGFR3 while VEGFR2 levels were unaffected showing that VEGFR2 and VEGFR3 are regulated in a differential manner by Notch [35]. These data have added a new player, VEGFR3, to the model used so far to describe the molecular crosstalk between VEGF and Notch pathways in angiogenesis.

In the context of sprouting angiogenesis, Notch signaling regulates not only the frequency of sprouts but also their ability to anastomose. Retinas of mice heterozygous for a myeloid-specific Notch1 mutation were characterized by long sprouts unable to anastomose and by lack of macrophages at the edge of vascular branch points [36].

Several studies have recognized the central role of Notch-mediated signaling also in cardiac development [37]. In

cardiomyocytes, the expression of Notch is not constant over time; it is high in embryonic and proliferating immature cells but disappears when the cells lose the ability to proliferate [38]. Nemir et al. observed that Notch signaling activation inhibits cardiac progenitor cells (CPCs) differentiation into cardiomyocytes [39]. The prolonged activation of Notch in adult cardiomyocytes may have different consequences. Campa et al. observed that in adult cardiomyocytes Notch activation is associated with the block of cell cycle progression and apoptosis, suggesting that a prolonged and uncontrolled activation of Notch can be fatal for these cells [40].

#### 4. Wnt/ $\beta$ -Catenin Signaling in Cardiovascular System

Notch signaling modulates endothelial homeostasis by crosstalking with other signaling pathways such as receptor tyrosine kinases (i.e., VEGFR2) [41–43] and estrogen receptor [41, 44]. Crosstalk between Notch and Wnt has also been described [41, 45–47]. The Wnt signaling pathway, also called Wnt/ $\beta$ -catenin signaling, plays a key role in vascular biology [45, 48]. Mice deficient for Wnt2 displayed vascular abnormalities including defective placental vasculature [49]. Knock-out mice for the Wnt receptor gene, Frizzled5, died in utero due to defects in yolk sac angiogenesis [50]. Defects of the  $\beta$ -catenin gene in ECs caused aberrant vascular patterning and increased vascular fragility [51].

The canonical Wnt signaling pathway is driven by  $\beta$ -catenin, a scaffold protein, linking the cytoplasmic tail of classical cadherins in the endothelium (vascular endothelial (VE) cadherin and N-cadherin) via  $\alpha$ -catenin to the actin cytoskeleton. Without Wnt stimulation, cytoplasmic  $\beta$ -catenin levels are kept low by a degradation complex, consisting of Axin, Adenomatous polyposis coli (APC), Casein kinase 1 (CK1a), and Glycogen synthase kinase 3- $\beta$  (GSK3- $\beta$ ). Binding of Wnt to its receptors Frizzled and lipoprotein receptor-related protein (LRP) leads to inhibition of the degradation complex function, enabling  $\beta$ -catenin signaling. Wnt allows  $\beta$ -catenin to accumulate and translocate to the nucleus where it binds to several transcription factors, for example, T-cell factor (TCF) and LEF-1 [52, 53].

Dishevelled (Dvl) is an essential adaptor protein for Wnt signaling that interacts with several molecules, including Axin, inactivating the  $\beta$ -catenin degradation complex [49–52]. Dvl has a dual role: it is an activator of downstream Wnt signaling and an inhibitor of Notch activity. Thus Dvl is a key regulator of cell-fate decisions in which Wnt and Notch have opposing effects [54].

The noncanonical Wnt pathway can be categorized largely into two classes, the Wnt/ $\text{Ca}^{2+}$  and Wnt/planar cell polarity (PCP) pathways. The Wnt/ $\text{Ca}^{2+}$  pathway, mediated by G-protein signaling, stimulates the release of intracellular  $\text{Ca}^{2+}$  and activation of  $\text{Ca}^{2+}$ -sensitive kinases, such as the protein kinase C and  $\text{Ca}^{2+}$ -calmodulin kinase II. PKC is a family of  $\text{Ca}^{2+}$ -dependent and  $\text{Ca}^{2+}$ -independent isoforms that have different distributions in various blood vessels, and individual members can have different roles in a plethora of biological and pathological events [54–56]. The PCP pathway, also

referred to as the Wnt/Jun-N-terminal kinase (JNK) pathway, was originally identified as a pathway affecting cytoskeletal reorganization [57]. This pathway activates small GTPases, including RhoA, Rac, Cdc42, and JNK.

#### 5. Crosstalk of Notch and Wnt/ $\beta$ -Catenin Signaling Pathways

Notch and Wnt signaling pathways can have opposing effects on cell-fate decisions with each pathway promoting an alternate outcome. For example, in both the skin and mammary gland, Wnt signaling promotes the maintenance of the stem cell fate whereas Notch signaling promotes lineage commitment and differentiation [54, 58–60]. In this case, the inhibition of Notch signaling would help to maintain the stem cell population. The Notch and Wnt pathways also have opposing effects at later steps within a cell lineage. For example, Notch and Wnt signaling influence terminal differentiation within the intestinal epithelium, with Notch activity biasing cells towards the absorptive fate and Wnt signaling favouring secretory cell differentiation [61–64]. Wnt pathway activation promotes neuronal differentiation and inhibits Notch signaling of primary human glioblastoma multiforme- (GBM-) derived cells [65].

Disregulation of Wnt-Notch signaling crosstalk alters early vascular development. Corada et al. [66] found that endothelial-specific early and sustained stabilization of Wnt/ $\beta$ -catenin induces activation of the Notch pathway by increasing the transcription of Dll4. This, in turn, prevents a correct endothelial cell differentiation, altering vascular remodeling and arteriovenous specification. Sustained Wnt/ $\beta$ -catenin signaling increases Dll4 in tumor vessels and induces Notch signaling that mediates a reduced angiogenic response and normalizes tumor vasculature [67]. Overexpression of Wnt/ $\beta$ -catenin signaling leads to alterations of vascular morphology by inhibiting angiogenesis, through stimulation of Dll4/Notch signaling. These effects of  $\beta$ -catenin were detectable only during embryonic vasculogenesis and angiogenesis but were lost at late stage of development or postnatally [68].

Yamamizu et al. [69] investigated signal transduction events downstream of the cAMP pathway in embryonic stem cells (ESCs) differentiation and demonstrated that simultaneous activation of Notch and  $\beta$ -catenin signaling can constructively reproduce the induction processes of arterial ECs from vascular progenitors expressing VEGFR2 through the formation of an arterial-specific protein complex. In particular these authors reported that RBP-Jk, NICD, and  $\beta$ -catenin formed a protein complex that promoted the transcription of genes specifically expressed in arterial but not venous districts in ESCs both *in vitro* and *in vivo*. Moreover, dual induction of NICD and  $\beta$ -catenin enhanced promoter activity of Notch target genes *in vitro* (Dll4, Hes1, and EphrinB2) and arterial gene expression during *in vivo* angiogenesis in adult mice.

The finding that a baseline level of Wnt and Notch activity can be detected during vascular development [70–74] and angiogenesis [67] suggests a mechanism in which the level of Wnt and Notch signaling is tightly balanced, that is, through

inhibition of Notch/CSL by Dvl [54], and crucial for proper vascular development.

Wnt signaling has been identified as a downstream target of Notch1 that regulates expression of cardiac transcription factors during mouse cardiogenesis and is essential for cardiac development facilitating transcription of target genes involved in cell fate regulation [75, 76]. Kwon et al. [77] recently demonstrated that Notch1 antagonizes Wnt/ $\beta$ -catenin signaling by reducing levels of active  $\beta$ -catenin in CPCs.

Crosstalk between Notch and Wnt pathways may be partially mediated by specific regulation of GSK3- $\beta$ , a multifunctional kinase that regulates many cellular processes including proliferation, differentiation, and apoptosis [78]. GSK3- $\beta$  is constitutively active in resting cells and is negatively regulated in response to external stimuli by phosphorylation on serine *via* activation of several kinases, including Akt and protein kinase C (PKC) [78]. Endoplasmic reticulum (ER) stress signaling through activation of GSK3 $\beta$  is involved in a mechanism of accelerated atherosclerosis in hyperglycemic, hyperhomocysteinemic, and high-fat-fed apolipoprotein E-deficient (apoE<sup>-/-</sup>) mouse models; McAlpine et al. showed that atherosclerosis can be attenuated by promoting GSK3 $\beta$  phosphorylation [79]. In diabetes mellitus, increased basal GSK3 $\beta$  activity contributes to accelerated EPC cellular senescence, effect reversed by small molecule antagonism of GSK3 $\beta$  which enhances cell-based therapy following vascular injury [80].

GSK3- $\beta$  directly binds to Notch and inhibits transcriptional activation of different Notch target genes [81–83]. Activated GSK3- $\beta$  reduced NICD degradation by the proteasome, while low GSK3- $\beta$  activity and high Notch signaling correlate with the highly proliferative, undifferentiated nature of EPCs [82]. Phosphorylation of Notch2 by GSK3- $\beta$  is reversed in the presence of Wnt1, resulting in the upregulation of Hes1 [81].

Integrin signaling is linked to Wnt signaling. Rallis et al. showed that, *in vitro*, Integrin-Linked Kinase (ILK) could phosphorylate GSK3- $\beta$  and, in turn, activate Wnt signaling. ILK can also activate Notch signaling. Therefore, the phosphorylation of GSK3- $\beta$  *via* ILK directs Wnt and, thereby, Notch signaling activation [84].

On the other hand a recent report [85] showed that GSK3- $\beta$  positively regulates the activity of Notch1 and 3 in VSMCs. Ectopic expression of GSK3- $\beta$  in VSMCs increased NICD levels, promoted CBF-1/RBP-J $\kappa$  transactivation, and enhanced Notch target genes expression. Coincidentally, inhibition of GSK3- $\beta$  activity using a pharmacological inhibitor or reduction in GSK3- $\beta$  levels by siRNA knockdown resulted in attenuation of Notch activity.

## 6. Could ROS Modulate Notch and Wnt/ $\beta$ -Catenin Signaling Pathways?

Studies conducted in the last several years have provided clear evidences that both Notch and Wnt/ $\beta$ -catenin pathways are regulated at least in part by Nox-derived ROS [86, 87].

Stretch-induced mechanotransduction in VSMCs is known to be regulated by redox signaling initiated by

stretch-induced activation of Nox and consequently increased ROS level [88, 89]. In response to stretch, ROS, in particular H<sub>2</sub>O<sub>2</sub>, contribute to the activation of arteriolar myogenic response, contraction, and reorientation, through p38 MAPK signaling activation in VSMCs [90–92]. Zhu et al. [93] showed that cyclic, uniaxial stretch of human VSMCs increased Nox derived-ROS formation and Notch3 activation. Catalase, an antioxidant enzyme that degrades H<sub>2</sub>O<sub>2</sub>, prevented the stretch-induced translocation of Notch3 to the nucleus, increased Hes1 expression, and decreased Notch3 extracellular domain.

In bone marrow-derived mesenchymal stem cells Boopathy et al. [94] observed upregulation of Notch1 and cardiogenic gene expression involving Wnt11 after a myocardial infarction, which induced increased level of H<sub>2</sub>O<sub>2</sub>. These results are in line with other authors: an increase in Wnt11 expression after oxidative stress injury induced cardiomyogenic differentiation of ESCs and mouse bone marrow mononuclear cells [95].

H<sub>2</sub>O<sub>2</sub> decreases the amount of nuclear  $\beta$ -catenin and TCF/LEF-dependent transcription in human embryonic kidney cells. Overexpression of Dvl1 abrogated H<sub>2</sub>O<sub>2</sub>-induced downregulation of  $\beta$ -catenin suggesting that H<sub>2</sub>O<sub>2</sub> negatively modulates Wnt signaling pathway through downregulation of  $\beta$ -catenin [96]. A recent study by Funato et al. [87, 97] identified a thioredoxin-related protein, nucleoredoxin (NRX) as a redox sensitive negative regulator of the canonical Wnt signaling through its interaction with Dvl. NRX usually interacts with Dvl but ROS cause dissociation of NRX from Dvl and enable Dvl to activate the downstream Wnt signaling pathway. Furthermore Kajla et al. [98] demonstrated that Wnt treatment of mouse intestinal cells induced ROS production through Nox1 via activation of the Rac1 guanine nucleotide exchange factor Vav2. Nox1-generated ROS oxidize and inactivate NRX, thereby releasing the NRX-dependent suppression of Wnt/ $\beta$ -catenin signaling through dissociation of NRX from Dvl. Nox1 siRNA inhibits cell response to Wnt, including stabilization of  $\beta$ -catenin, expression of cyclin D1, and c-Myc via the TCF transcription factor.

Msx2, a profibrotic, proosteogenic transcription factor upregulates the expression of multiple Wnt ligands during angiogenesis [99] and enhances aortic canonical Wnt signaling [100]. Msx2-Wnt signaling pathways are induced by tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) in arterial myofibroblast via tumor necrosis factor receptor 1 (TNFR1). *In vitro* and *in vivo* gene expression studies established that Nox/mitochondria-derived ROS inhibition reduces Msx2 induction by TNF $\alpha$ . Wnt7b as well as  $\beta$ -catenin levels were also reduced, suggesting that ROS metabolism contributes to TNF $\alpha$  induction of Msx2 and Wnt signaling in myofibroblasts via TNFR1 [101].

APC mutation causes Wnt signaling activation and is commonly found in colorectal cancer [102]. Myant et al. [103] showed that activation of Rac1, a component of Nox protein complex, is required for Wnt-driven intestinal stem cell transformation through ROS production and NF- $\kappa$ B activation. Accordingly, increased ROS might contribute to tumorigenesis by activating specific signaling pathways in different cell types [104], one of which is Wnt signaling.

The cardioprotective effect of ischemic preconditioning (IPC) is abolished by overexpression of secreted frizzled protein 1 (sFRP1), an antagonist of the Wnt/Frizzled pathway, and this effect is related to the ability of sFRP1 to decrease the phosphorylation/inhibition of GSK3- $\beta$  [105]. Cardioprotection involves a link between the mTOR prosurvival pathway and the Wnt pathway *via* ROS that promote activation of Akt and inhibition of GSK3- $\beta$ . The disruption of the Wnt pathway modulates this loop and induces GSK3- $\beta$  activation [106].

Coant et al. [86] reported that direct or indirect redox modulation of the PI3K/Akt and Wnt signaling pathways by Nox1 results in phosphorylation/inhibition of GSK3- $\beta$  and  $\beta$ -catenin translocation into the nucleus as well as Notch1 activation. They show that loss of Nox1 results in increased PTEN activity that in turn inhibits Akt signaling pathway, as well as Wnt/ $\beta$ -catenin and Notch1 signaling. As previously discussed, GSK3- $\beta$  is an important mediator of Notch-Wnt crosstalk; therefore, it could be a key player by which ROS regulate both pathways.

Taken together these results suggest that redox-dependent regulation of Notch and Wnt/ $\beta$ -catenin signaling could provide further insight into their involvement in vascular biology.

## 7. Conclusion and Future Perspectives

ROS have long been deemed as noxious molecules in cardiovascular diseases, including systemic and pulmonary hypertension, atherosclerosis, cardiac hypertrophy, and heart failure. With years of efforts, ROS are becoming increasingly recognized as important modulator for a variety of biological functions and pathophysiological states. Recent evidences suggest an even more significant role of ROS: Notch and Wnt/ $\beta$ -catenin signaling modulation. A clear distinction between Notch and Wnt responses is vital for appropriate and robust cell-fate decisions, and ROS modulation of these signaling pathways would provide clues for clinical strategies and drug discovery targeting cardiovascular diseases and cancer.

Above we have discussed how ROS modulation of Notch and Wnt signaling regulates vascular development in different aspects, including stem cells differentiation, angiogenesis, VEGF signaling, endothelial as well as cardiac progenitor cells recruitment, and vascular cell migration. Nonetheless, more details regarding the ROS signaling and pathophysiological functions remain to be elucidated. A deeper insight into the mechanism of how ROS affect normal vascular development, especially CPCs, VSMCs, and ECs differentiation from stem cells, could contribute to a brighter future for regenerative medicine in cardiovascular therapies. Factors that selectively control ROS modulation of Notch and Wnt/ $\beta$ -catenin signaling pathways could have therapeutic effects repressing angiogenesis in tumours or favouring it in ischemic tissues.

## Abbreviations

ROS: Reactive oxygen species  
Nox: NAD(P)H oxidase

VEGF: Vascular endothelial growth factor  
TNF $\alpha$ : Tumor necrosis factor  $\alpha$   
GSK3- $\beta$ : Glycogen synthase kinase 3- $\beta$   
Dll: Delta-like ligand  
Hes: Hairy/enhancer of split  
Hey: Hes-related proteins  
Dvl: Dishevelled  
NRX: Nucleoredoxin  
HUVECs: Human umbilical vein endothelial cells  
EPCs: Endothelial progenitor cells  
CPCs: Cardiac progenitor cells  
ESCs: Embryonic stem cells  
VSMCs: Vascular smooth muscle cells.

## Conflict of Interests

The authors declare no competing financial interests.

## Acknowledgments

The authors are grateful to Dr. Laura Landi for her suggestions and comments, which have contributed to the revision of the paper. This work was supported by a grant from Fondazione Annamaria Sechi per il Cuore (FASC), Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

## References



- [1] T. Gaziano, K. S. Reddy, F. Paccaud, S. Horton, and V. Chaturvedi, *Cardiovascular Disease*. NBK11767, 2006.
- [2] K. Sugamura and J. F. Keaney Jr., "Reactive oxygen species in cardiovascular disease," *Free Radical Biology and Medicine*, vol. 51, pp. 978–992, 2011.
- [3] J. Oshikawa, S.-J. Kim, E. Furuta et al., "Novel role of p66shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cells," *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 302, no. 3, pp. H724–H732, 2012.
- [4] C. E. Oon and A. L. Harris, "New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis," *Biochemical Society Transactions*, vol. 39, no. 6, pp. 1612–1618, 2011.
- [5] K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, and R. W. Alexander, "Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells," *Circulation Research*, vol. 74, no. 6, pp. 1141–1148, 1994.
- [6] M. Sundaresan, Z.-X. Yu, V. J. Ferrans, K. Irani, and T. Finkel, "Requirement for generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction," *Science*, vol. 270, no. 5234, pp. 296–299, 1995.
- [7] B. S. Wung, J. J. Cheng, H. J. Hsieh, Y. J. Shyy, and D. L. Wang, "Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1," *Circulation Research*, vol. 81, no. 1, pp. 1–7, 1997.
- [8] S. Rajagopalan, S. Kurz, T. Münzel et al., "Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone," *Journal of Clinical Investigation*, vol. 97, no. 8, pp. 1916–1923, 1996.

- [9] K. K. Griendling and G. A. FitzGerald, "Oxidative stress and cardiovascular injury: part II: animal and human studies," *Circulation*, vol. 108, no. 17, pp. 2034–2040, 2003.
- [10] B. Halliwell, "Current status review: free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis," *British Journal of Experimental Pathology*, vol. 70, no. 6, pp. 737–757, 1989.
- [11] K. K. Griendling and G. A. FitzGerald, "Oxidative stress and cardiovascular injury: part II: animal and human studies," *Circulation*, vol. 108, no. 17, pp. 2034–2040, 2003.
- [12] J. B. Laursen, S. Rajagopalan, Z. Galis, M. Tarpey, B. A. Freeman, and D. G. Harrison, "Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension," *Circulation*, vol. 95, no. 3, pp. 588–593, 1997.
- [13] G. B. Mancini, G. C. Henry, C. Macaya et al., "Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study," *Circulation*, vol. 94, pp. 258–265, 1996.
- [14] S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators," *The New England Journal of Medicine*, vol. 342, pp. 145–153, 2000.
- [15] T. J. Guzik, N. E. Hoch, K. A. Brown et al., "Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction," *Journal of Experimental Medicine*, vol. 204, no. 10, pp. 2449–2460, 2007.
- [16] K. Satoh, P. Nigro, A. Zeidan et al., "Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 5, pp. 1116–1123, 2011.
- [17] K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, "NAD(P)H oxidase: role in cardiovascular biology and disease," *Circulation Research*, vol. 86, no. 5, pp. 494–501, 2000.
- [18] S. G. Rhee, Y. S. Bae, S. R. Lee, and J. Kwon, "Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation," *Science's STKE*, vol. 2000, no. 53, p. pe1, 2000.
- [19] J. D. Lambeth, "NOX enzymes and the biology of reactive oxygen," *Nature Reviews Immunology*, vol. 4, pp. 181–189, 2004.
- [20] L. Ahmarani, L. Avedanian, J. Al-Khoury, C. Perreault, D. Jacques, and G. Bkaily, "Whole-cell and nuclear NADPH oxidases levels and distribution in human endocardial endothelial, vascular smooth muscle, and vascular endothelial cells," *Canadian Journal of Physiology and Pharmacology*, vol. 91, pp. 71–79, 2013.
- [21] M. Ushio-Fukai, Y. Tang, T. Fukai et al., "Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis," *Circulation Research*, vol. 91, no. 12, pp. 1160–1167, 2002.
- [22] M. Ushio-Fukai, "Redox signaling in angiogenesis: role of NADPH oxidase," *Cardiovascular Research*, vol. 71, pp. 226–235, 2006.
- [23] J. J. Khatri, C. Johnson, R. Magid et al., "Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma," *Circulation*, vol. 109, no. 4, pp. 520–525, 2004.
- [24] S. R. Datta, H. Peshavariya, G. J. Dusting, K. Mahadev, B. J. Goldstein, and F. Jiang, "Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 27, no. 11, pp. 2319–2324, 2007.
- [25] P. Vallet, Y. Charnay, K. Steger et al., "Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia," *Neuroscience*, vol. 132, no. 2, pp. 233–238, 2005.
- [26] M. Zhang, A. C. Brewer, K. Schröder et al., "NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 42, pp. 18121–18126, 2010.
- [27] N. Urao and M. Ushio-Fukai, "Redox regulation of stem/progenitor cells and bone marrow niche," *Free Radical Biology & Medicine*, vol. 54, pp. 26–39, 2013.
- [28] C. M. Souza, D. Davidson, I. Rhee, J. P. Gratton, E. C. Davis, and A. Veillette, "The phosphatase PTP-PEST/PTPN12 regulates endothelial cell migration and adhesion, but not permeability, and controls vascular development and embryonic viability," *The Journal of Biological Chemistry*, vol. 287, pp. 43180–43190, 2012.
- [29] G. Leoni, A. Alam, P. A. Neumann et al., "Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair," *The Journal of Clinical Investigation*, vol. 123, pp. 443–454, 2013.
- [30] S. Artavanis-Tsakonas, M. D. Rand, and R. J. Lake, "Notch signaling: cell fate control and signal integration in development," *Science*, vol. 284, no. 5415, pp. 770–776, 1999.
- [31] L. M. Christian, "The ADAM family: insights into Notch proteolysis," *Fly*, vol. 6, pp. 30–34, 2012.
- [32] L. Miele, "Notch signaling," *Clinical Cancer Research*, vol. 12, pp. 1074–1079, 2006.
- [33] Z. A. Al Haj and P. Madeddu, "Notch signalling in ischaemia-induced angiogenesis," *Biochemical Society Transactions*, vol. 37, pp. 1221–1227, 2009.
- [34] P. Rizzo, L. Miele, and R. Ferrari, "The Notch pathway: a crossroad between the life and death of the endothelium," *European Heart Journal*, vol. 34, pp. 2504–2509, 2013.
- [35] R. Benedito, S. F. Rocha, M. Woeste et al., "Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling," *Nature*, vol. 484, no. 7392, pp. 110–114, 2012.
- [36] H. H. Outtz, I. W. Tattersall, N. M. Kofler, N. Steinbach, and J. Kitajewski, "Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice," *Blood*, vol. 118, no. 12, pp. 3436–3439, 2011.
- [37] J. L. de la Pompa and J. A. Epstein, "Coordinating tissue interactions: notch signaling in cardiac development and disease," *Developmental Cell*, vol. 22, pp. 244–254, 2012.
- [38] C. Collesi, L. Zentilin, G. Sinagra, and M. Giacca, "Notch1 signaling stimulates proliferation of immature cardiomyocytes," *Journal of Cell Biology*, vol. 183, no. 1, pp. 117–128, 2008.
- [39] M. Nemir, A. Croquelois, T. Pedrazzini, and F. Radtke, "Induction of cardiogenesis in embryonic stem cells via downregulation of Notch1 signaling," *Circulation Research*, vol. 98, no. 12, pp. 1471–1478, 2006.
- [40] V. M. Campa, R. Gutiérrez-Lanza, F. Cerignoli et al., "Notch activates cell cycle reentry and progression in quiescent cardiomyocytes," *Journal of Cell Biology*, vol. 183, no. 1, pp. 129–141, 2008.
- [41] Y. Funahashi, C. J. Shawber, M. Vorontchikhina, A. Sharma, H. H. Outtz, and J. Kitajewski, "Notch regulates the angiogenic response via induction of VEGFR-1," *Journal of Angiogenesis Research*, vol. 2, no. 1, article 3, 2010.

- [42] M. Koyanagi, P. Bushoven, M. Iwasaki, C. Urbich, A. M. Zeiher, and S. Dimmeler, "Notch signaling contributes to the expression of cardiac markers in human circulating progenitor cells," *Circulation Research*, vol. 101, no. 11, pp. 1139–1145, 2007.
- [43] J.-L. Li, R. C. A. Sainson, C. E. Oon et al., "DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo," *Cancer Research*, vol. 71, no. 18, pp. 6073–6083, 2011.
- [44] C. Caliceti, G. Aquila, M. Pannella et al., "17beta-estradiol enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis in human endothelial cells," *PLoS One*, vol. 8, Article ID e71440, 2013.
- [45] G. M. Collu, A. Hidalgo-Sastre, A. Acar et al., "Dishevelled limits Notch signalling through inhibition of CSL," *Development*, vol. 139, pp. 4405–4415, 2012.
- [46] P. Hayward, K. Brennan, P. Sanders et al., "Notch modulates Wnt signalling by associating with Armadillo/ $\beta$ -catenin and regulating its transcriptional activity," *Development*, vol. 132, no. 8, pp. 1819–1830, 2005.
- [47] M. Shin, H. Nagai, and G. Sheng, "Notch mediates Wnt and BMP signals in the early separation of smooth muscle progenitors and blood/endothelial common progenitors," *Development*, vol. 136, no. 4, pp. 595–603, 2009.
- [48] A. M. Goodwin and P. A. D'Amore, "Wnt signaling in the vasculature," *Angiogenesis*, vol. 5, no. 1-2, pp. 1–9, 2002.
- [49] S. J. Monkley, S. J. Delaney, D. J. Pennisi, J. H. Christiansen, and B. J. Wainwright, "Targeted disruption of the Wnt2 gene results in placentation defects," *Development*, vol. 122, no. 11, pp. 3343–3353, 1996.
- [50] T.-O. Ishikawa, Y. Tamai, A. M. Zorn et al., "Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis," *Development*, vol. 128, no. 1, pp. 25–33, 2001.
- [51] A. Cattelino, S. Liebner, R. Gallini et al., "The conditional inactivation of the  $\beta$ -catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility," *Journal of Cell Biology*, vol. 162, no. 6, pp. 1111–1122, 2003.
- [52] M. Bienz and H. Clevers, "Linking colorectal cancer to Wnt signaling," *Cell*, vol. 103, no. 2, pp. 311–320, 2000.
- [53] B. M. Gumbiner, "Carcinogenesis: a balance between  $\beta$ -catenin and APC," *Current Biology*, vol. 7, no. 7, pp. R443–R446, 1997.
- [54] G. M. Collu, A. Hidalgo-Sastre, A. Acar et al., "Dishevelled limits Notch signalling through inhibition of CSL," *Development*, vol. 139, pp. 4405–4415, 2012.
- [55] M. Kuhl, L. C. Sheldahl, M. Park, J. R. Miller, and R. T. Moon, "The Wnt/Ca<sup>2+</sup> pathway: a new vertebrate Wnt signaling pathway takes shape," *Trends in Genetics*, vol. 16, no. 7, pp. 279–283, 2000.
- [56] M. Kuhl, L. C. Sheldahl, C. C. Malbon, and R. T. Moon, "Ca<sup>2+</sup>/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in *Xenopus*," *Journal of Biological Chemistry*, vol. 275, no. 17, pp. 12701–12711, 2000.
- [57] M. Simons and M. Mlodzik, "Planar cell polarity signaling: from fly development to human disease," *Annual Review of Genetics*, vol. 42, pp. 517–540, 2008.
- [58] T. Bouras, B. Pal, F. Vaillant et al., "Notch signaling regulates mammary stem cell function and luminal cell-fate commitment," *Cell Stem Cell*, vol. 3, no. 4, pp. 429–441, 2008.
- [59] S. Lowell, P. Jones, I. le Roux, J. Dunne, and F. M. Watt, "Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters," *Current Biology*, vol. 10, no. 9, pp. 491–500, 2000.
- [60] Y. A. Zeng and R. Nusse, "Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture," *Cell Stem Cell*, vol. 6, no. 6, pp. 568–577, 2010.
- [61] S. Fre, M. Huyghe, P. Mourikis, S. Robine, D. Louvard, and S. Artavanis-Tsakonas, "Notch signals control the fate of immature progenitor cells in the intestine," *Nature*, vol. 435, no. 7044, pp. 964–968, 2005.
- [62] B. Z. Stanger, R. Datar, L. C. Murtaugh, and D. A. Melton, "Direct regulation of intestinal fate by Notch," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 35, pp. 12443–12448, 2005.
- [63] J. H. van Es, M. E. van Gijn, O. Riccio et al., "Notch/ $\gamma$ -secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells," *Nature*, vol. 435, no. 7044, pp. 959–963, 2005.
- [64] J. H. van Es, P. Jay, A. Gregorieff et al., "Wnt signalling induces maturation of Paneth cells in intestinal crypts," *Nature Cell Biology*, vol. 7, no. 4, pp. 381–386, 2005.
- [65] E. Rampazzo, L. Persano, F. Pistollato et al., "Wnt activation promotes neuronal differentiation of glioblastoma," *Cell Death & Disease*, vol. 4, p. e500, 2013.
- [66] M. Corada, D. Nyqvist, F. Orsenigo et al., "The Wnt/ $\beta$ -catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling," *Developmental Cell*, vol. 18, no. 6, pp. 938–949, 2010.
- [67] M. Reis, C. J. Czupalla, N. Ziegler et al., "Endothelial Wnt/ $\beta$ -catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression," *The Journal of Experimental Medicine*, vol. 209, pp. 1611–1627, 2012.
- [68] H. Clevers, "Wnt/ $\beta$ -catenin signaling in development and disease," *Cell*, vol. 127, pp. 469–480, 2006.
- [69] K. Yamamizu, T. Matsunaga, H. Uosaki et al., "Convergence of Notch and  $\beta$ -catenin signaling induces arterial fate in vascular progenitors," *Journal of Cell Biology*, vol. 189, no. 2, pp. 325–338, 2010.
- [70] R. Daneman, D. Agalliu, L. Zhou, F. Kuhnert, C. J. Kuo, and B. A. Barres, "Wnt/ $\beta$ -catenin signaling is required for CNS, but not non-CNS, angiogenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, pp. 641–646, 2009.
- [71] S. Liebner, M. Corada, T. Bangsow et al., "Wnt/ $\beta$ -catenin signaling controls development of the blood–brain barrier," *Journal of Cell Biology*, vol. 183, no. 3, pp. 409–417, 2008.
- [72] S. Maretto, M. Cordenonsi, S. Dupont et al., "Mapping Wnt/ $\beta$ -catenin signaling during mouse development and in colorectal tumors," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 6, pp. 3299–3304, 2003.
- [73] L.-K. Phng and H. Gerhardt, "Angiogenesis: a team effort coordinated by notch," *Developmental Cell*, vol. 16, no. 2, pp. 196–208, 2009.
- [74] J. M. Stenman, J. Rajagopal, T. J. Carroll, M. Ishibashi, J. McMahon, and A. P. McMahon, "Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature," *Science*, vol. 322, no. 5905, pp. 1247–1250, 2008.
- [75] E. D. Cohen, M. F. Miller, Z. Wang, R. T. Moon, and E. E. Morrisey, "Wnt5a and Wnt11 are essential for second heart field progenitor development," *Development*, vol. 139, pp. 1931–1940, 2012.
- [76] A. Klaus, M. Muller, H. Schulz, Y. Saga, J. F. Martin, and W. Birchmeier, "Wnt/ $\beta$ -catenin and Bmp signals control

- distinct sets of transcription factors in cardiac progenitor cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, pp. 10921–10926, 2012.
- [77] S. M. Kwon, C. Alev, and T. Asahara, "The role of notch signaling in endothelial progenitor cell biology," *Trends in Cardiovascular Medicine*, vol. 19, pp. 170–173, 2009.
- [78] T. Force and J. R. Woodgett, "Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development," *Journal of Biological Chemistry*, vol. 284, no. 15, pp. 9643–9647, 2009.
- [79] C. S. McAlpine, A. J. Bowes, M. I. Khan, Y. Shi, and G. H. Werstuck, "Endoplasmic reticulum stress and glycogen synthase kinase-3 $\beta$  activation in apolipoprotein E-deficient mouse models of accelerated atherosclerosis," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, pp. 82–91, 2012.
- [80] B. Hibbert, J. R. Lavoie, X. Ma et al., "Glycogen synthase kinase-3 $\beta$  inhibition augments diabetic endothelial progenitor cell Abundance and functionality via cathepsin B: a novel therapeutic opportunity for arterial repair," *Diabetes*, 2013.
- [81] L. Espinosa, J. Inglés-Esteve, C. Aguilera, and A. Bigas, "Phosphorylation by glycogen synthase kinase-3 $\beta$  down-regulates Notch activity, a link for Notch and Wnt pathways," *Journal of Biological Chemistry*, vol. 278, no. 34, pp. 32227–32235, 2003.
- [82] D. Foltz, M. C. Santiago, B. E. Berechid, and J. S. Nye, "Glycogen synthase kinase-3 $\beta$  modulates notch signaling and stability," *Current Biology*, vol. 12, no. 12, pp. 1006–1011, 2002.
- [83] Y. H. Jin, H. Kim, M. Oh, H. Ki, and K. Kim, "Regulation of Notch1/NICD and Hes1 expressions by GSK-3 $\alpha/\beta$ ," *Molecules and Cells*, vol. 27, no. 1, pp. 15–19, 2009.
- [84] C. Rallis, S. M. Pinchin, and D. Ish-Horowicz, "Cell-autonomous integrin control of Wnt and Notch signalling during somitogenesis," *Development*, vol. 137, no. 21, pp. 3591–3601, 2010.
- [85] S. Guha, J. P. Cullen, D. Morrow et al., "Glycogen synthase kinase 3 beta positively regulates Notch signaling in vascular smooth muscle cells: role in cell proliferation and survival," *Basic Research in Cardiology*, vol. 106, no. 5, pp. 773–785, 2011.
- [86] N. Coant, S. B. Mkaddem, E. Pedruzzi et al., "NADPH oxidase 1 modulates WNT and NOTCH1 signaling to control the fate of proliferative progenitor cells in the colon," *Molecular and Cellular Biology*, vol. 30, no. 11, pp. 2636–2650, 2010.
- [87] Y. Funato and H. Miki, "Redox regulation of Wnt signalling via nucleoredoxin," *Free Radical Research*, vol. 44, no. 4, pp. 379–388, 2010.
- [88] E. Mata-Greenwood, A. Grobe, S. Kumar, Y. Noskina, and S. M. Black, "Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF- $\beta$ 1 and reactive oxygen species: a requirement for NAD(P)H oxidase," *American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 289, no. 2, pp. L288–L298, 2005.
- [89] T. Ohmine, Y. Miwa, F. Takahashi-Yanaga, S. Morimoto, Y. Maehara, and T. Sasaguri, "The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells," *Hypertension Research*, vol. 32, no. 8, pp. 690–699, 2009.
- [90] Q. Chen, W. Li, Z. Quan, and B. E. Sumpio, "Modulation of vascular smooth muscle cell alignment by cyclic strain is dependent on reactive oxygen species and P38 mitogen-activated protein kinase," *Journal of Vascular Surgery*, vol. 37, no. 3, pp. 660–668, 2003.
- [91] P. T. Nowicki, S. Flavahan, H. Hassanain et al., "Redox signaling of the arteriolar myogenic response," *Circulation Research*, vol. 89, no. 2, pp. 114–116, 2001.
- [92] B. Su, S. Mitra, H. Gregg et al., "Redox regulation of vascular smooth muscle cell differentiation," *Circulation Research*, vol. 89, no. 1, pp. 39–46, 2001.
- [93] J.-H. Zhu, C.-L. Chen, S. Flavahan, J. Harr, B. Su, and N. A. Flavahan, "Cyclic stretch stimulates vascular smooth muscle cell alignment by redoxdependent activation of Notch3," *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 300, no. 5, pp. H1770–H1780, 2011.
- [94] A. V. Boopathy, K. D. Pendergrass, P. L. Che, Y. S. Yoon, and M. E. Davis, "Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells," *Stem Cell Research & Therapy*, vol. 4, p. 43, 2013.
- [95] M. P. Flaherty, A. Abdel-Latif, Q. Li et al., "Noncanonical Wnt11 signaling is sufficient to induce cardiomyogenic differentiation in unfractionated bone marrow mononuclear cells," *Circulation*, vol. 117, no. 17, pp. 2241–2252, 2008.
- [96] S. Y. Shin, C. G. Kim, E. H. Jho et al., "Hydrogen peroxide negatively modulates Wnt signaling through downregulation of beta-catenin," *Cancer Letters*, vol. 212, pp. 225–231, 2004.
- [97] Y. Funato, T. Terabayashi, R. Sakamoto et al., "Nucleoredoxin sustains Wnt/ $\beta$ -catenin signaling by retaining a pool of inactive dishevelled protein," *Current Biology*, vol. 20, no. 21, pp. 1945–1952, 2010.
- [98] S. Kajla, A. S. Mondol, A. Nagasawa et al., "A crucial role for Nox 1 in redox-dependent regulation of Wnt-beta-catenin signaling," *The FASEB Journal*, vol. 26, pp. 2049–2059, 2012.
- [99] A. M. Goodwin and P. A. D'Amore, "Wnt signaling in the vasculature," *Angiogenesis*, vol. 5, no. 1-2, pp. 1–9, 2002.
- [100] B. Mao, W. Wu, G. Davidson et al., "Kremen proteins are Dickkopf receptors that regulate Wnt/ $\beta$ -catenin signalling," *Nature*, vol. 417, no. 6889, pp. 664–667, 2002.
- [101] C. F. Lai, J. S. Shao, A. Behrmann, K. Krcchma, S. L. Cheng, and D. A. Towler, "TNFR1-activated reactive oxidative species signals up-regulate osteogenic Mx2 programs in aortic myofibroblasts," *Endocrinology*, vol. 153, pp. 3897–3910, 2012.
- [102] E. R. Fearon, "Molecular genetics of colorectal cancer," *Annual Review of Pathology*, vol. 6, pp. 479–507, 2011.
- [103] K. B. Myant, P. Cammareri, E. J. McGhee et al., "ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation," *Cell Stem Cell*, vol. 12, pp. 761–773, 2013.
- [104] T. Maraldi, C. Prata, D. Fiorentini, L. Zamboni, L. Landi, and G. Hakim, "Induction of apoptosis in a human leukemic cell line via reactive oxygen species modulation by antioxidants," *Free Radical Biology and Medicine*, vol. 46, no. 2, pp. 244–252, 2009.
- [105] L. Barandon, P. Dufourcq, P. Costet et al., "Involvement of FrzA/sFRP-1 and the Wnt/Frizzled pathway in ischemic preconditioning," *Circulation Research*, vol. 96, no. 12, pp. 1299–1306, 2005.
- [106] F. Vigneron, P. Dos Santos, S. Lemoine et al., "GSK-3 $\beta$  at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways," *Cardiovascular Research*, vol. 90, no. 1, pp. 49–56, 2011.





**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

